Skip to main navigation
Alpine Immune Sciences Alpine Immune Sciences

Main navigation

  • About Us
    • At a Glance
    • Management Team
    • Board of Directors
    • Scientific Advisors
    • Partners
    • Contact Us
  • Pipeline & Programs
    • Pipeline
    • ALPN-101
    • ALPN-202
    • ALPN-303
    • Science & Platform
    • Scientific Publications
  • Clinical Trials
  • Investors
    • Stock Information
    • Analyst Coverage
    • News Release
    • Events & Presentations
    • SEC Filings
    • Governance
    • FAQs
    • Investors Contact
  • Careers
  • No menu assigned!

News Releases

Investor Relations - Horizontal

news releases  |  events  |  sec filings  |  governance  | 

board of directors  |  leadership  |  documents  |  committee composition  | 

faqs  |  investors contact  | 
  • May 26, 2020
    Summary ToggleAlpine Immune Sciences to Participate in Fireside Chat at the Jefferies Virtual Global Healthcare Conference
    SEATTLE --(BUSINESS WIRE)--May 26, 2020-- Alpine Immune Sciences, Inc. (NASDAQ: ALPN), a leading clinical-stage immunotherapy company focused on developing innovative treatments for cancer and autoimmune/inflammatory diseases, today announced its participation in an analyst-led fireside chat at the
    Read More
  • May 14, 2020
    Summary ToggleAlpine Immune Sciences Reports First Quarter 2020 Financial Results and Provides Company Update
    - Granted FDA Orphan Drug Designations for ALPN-101 in Acute GVHD - - BALANCE and NEON-1 Trials Open for Enrollment - SEATTLE --(BUSINESS WIRE)--May 14, 2020-- Alpine Immune Sciences, Inc. (NASDAQ:ALPN), a leading clinical-stage immunotherapy company focused on developing innovative treatments for
    Read More
  • April 27, 2020
    Summary ToggleAlpine Immune Sciences Presents Design of the ALPN-202 Phase 1 Study (NEON-1) at AACR Virtual Annual Meeting I
    - NEON-1 is now open for enrollment for patients with advanced malignancies - SEATTLE --(BUSINESS WIRE)--Apr. 27, 2020-- Alpine Immune Sciences, Inc. (NASDAQ: ALPN), a leading clinical-stage immunotherapy company focused on developing innovative treatments for cancer and autoimmune/inflammatory
    Read More
  • April 20, 2020
    Summary ToggleAlpine Immune Sciences Announces Poster Presentation at AACR Virtual Annual Meeting I
    SEATTLE --(BUSINESS WIRE)--Apr. 20, 2020-- Alpine Immune Sciences, Inc. (NASDAQ: ALPN), a leading clinical-stage immunotherapy company focused on developing innovative treatments for cancer and autoimmune/inflammatory diseases, today announced the company will present a poster at the AACR Virtual
    Read More
  • March 30, 2020
    Summary ToggleAlpine Immune Sciences Provides Corporate Update and Reports Fourth Quarter and Full Year 2019 Financial Results
    Completion of Phase 1 Study for Lead Autoimmune/Inflammatory Disease Program, ALPN-101 BALANCE Trial of ALPN-101 in Acute GVHD Open for Enrollment NEON-1 Trial of ALPN-202 in Advanced Malignancies Open for Enrollment Orphan Drug Designations by the U.S.
    Read More
  • March 18, 2020
    Summary ToggleAlpine Immune Sciences’ ALPN-101 Receives FDA Orphan Drug Designations for the Prevention and Treatment of Acute Graft Versus Host Disease
    Company to Hold Conference Call to Discuss Fourth Quarter and Full Year 2019 Results on March 30, 2020 SEATTLE --(BUSINESS WIRE)-- Alpine Immune Sciences, Inc. (NASDAQ:ALPN) , a leading clinical-stage immunotherapy company focused on developing innovative treatments for cancer and
    Read More
  • March 2, 2020
    Summary ToggleAlpine Immune Sciences Announces Cancellation of Presentation and Webcast at the Cowen 40th Annual Healthcare Conference
    SEATTLE --(BUSINESS WIRE)-- Alpine Immune Sciences, Inc. (NASDAQ:ALPN) announced today the cancellation of the Company’s presentation and webcast at the Cowen 40 th Annual Healthcare Conference scheduled for Tuesday, March 3, 2020 at 11:20 am. Eastern Time .
    Read More
  • February 25, 2020
    Summary ToggleAlpine Immune Sciences to Present at Two Upcoming Healthcare Investor Conferences
    SEATTLE --(BUSINESS WIRE)--Feb. 25, 2020-- Alpine Immune Sciences, Inc. (NASDAQ:ALPN), a leading immunotherapy company focused on developing treatments for autoimmune/inflammatory diseases and cancer, today announced the company will present at two upcoming investor healthcare conferences in March.
    Read More
  • January 24, 2020
    Summary ToggleAlpine Immune Sciences Presents New Preclinical Data at 2020 Crohn’s & Colitis Congress   ALPN-101 efficacious in a preclinical model of inflammatory bowel disease
    SEATTLE --(BUSINESS WIRE)--Jan. 24, 2020-- Alpine Immune Sciences, Inc. (NASDAQ:ALPN), a leading clinical-stage immunotherapy company focused on developing innovative treatments for cancer and autoimmune/inflammatory diseases, presented new preclinical data on its lead autoimmune/inflammatory
    Read More
  • January 6, 2020
    Summary ToggleAlpine Immune Sciences Announces Poster Presentation at 2020 Crohn’s & Colitis Congress
    SEATTLE --(BUSINESS WIRE)--Jan. 6, 2020-- Alpine Immune Sciences, Inc. (NASDAQ:ALPN), a leading clinical-stage immunotherapy company focused on developing innovative treatments for cancer and autoimmune/inflammatory diseases, today announced the company will present a poster at the 2020 Crohn’s &
    Read More

Pagination

  • First page First
  • Previous page Previous
  • …
  • Page 2
  • Current page 3
  • Page 4
  • Page 5
  • …
  • Next page Next
  • Last page Last
Displaying 21 - 30 of 98 results

Toolkit

  • Contact Us
  • Email Alerts
  • RSS Feeds
  • Print Page
  • Email Page

Contact

188 East Blaine Street
Suite 200
Seattle, WA
98102
206-788-4545

Sitemap

  • About Us
  • Pipelines & Programs
  • Clinical Trials
  • Investors
  • Careers
  • Contact Us
  • Legal

Twitter

@AlpineImmuneSci

LATEST TWEETS

Tweets by @AlpineImmuneSci

© 2021 Alpine Immune Sciences. All Rights Reserved, Alpine Immune Sciences Inc.

Investor Relations - Horizontal

  • News Releases
  • Events
  • SEC Filings
  • Governance
    • Board of Directors
    • Leadership
    • Documents
    • Committee Composition
  • FAQs
  • Investors Contact